Related Experiment Video

Updated: Aug 30, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

[Antipneumococcal vaccines in sickle-cell anemia and asplenia]

R Cohen1

  • 1Service de bactériologie Centre hospitalier intercommunal de Créteil (94).

Presse Medicale (Paris, France : 1983)
|November 25, 2003
PubMed

Insights

Patients with asplenia or sickle-cell anemia require vaccination and antibiotics to prevent serious infections from encapsulated bacteria like pneumococci. Vaccines such as Pneumo 23 and Prevenar, along with other immunizations, are crucial for prevention.

Area of Science:

  • Infectious Diseases
  • Immunology
  • Bacteriology

Context:

  • Patients with asplenia and sickle-cell anemia are highly vulnerable to encapsulated bacterial infections, including Streptococcus pneumoniae, Haemophilus influenzae type b, and Neisseria meningitidis.
  • These infections pose significant risks and necessitate robust preventive strategies.

Purpose:

  • To review and highlight key vaccination and antibiotic prophylaxis strategies for preventing invasive bacterial infections in asplenic and sickle-cell anemia patients.
  • To discuss the role and efficacy of different vaccines, including polysaccharide and conjugate vaccines, in managing these at-risk populations.

Summary:

  • Pneumococcal vaccination, using both 23-valent polysaccharide (Pneumo 23) and 7-valent conjugate (Prevenar) vaccines, is essential for preventing pneumococcal infections.
  • Conjugate vaccines offer enhanced efficacy, particularly against antibiotic-resistant strains, and can potentiate antibiotic prophylaxis.
  • Recommendations also include conjugated group C meningococcal vaccines and routine Haemophilus influenzae type b vaccination for infants.

Impact:

  • Improved prevention of severe infections in vulnerable populations.
  • Optimized use of antibiotic prophylaxis through enhanced vaccine efficacy.
  • Reduced morbidity and mortality associated with encapsulated bacterial pathogens in asplenic and sickle-cell disease patients.

More Related Videos

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens08:47

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Published on: April 5, 2019

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: